Caris Life Sciences Expands AI Insights Portfolio to Predict Ovarian Cancer Platinum Resistance

Caris Life Sciences expanded its AI Insights portfolio with a new signature to predict platinum resistance in ovarian cancer. The tool analyzes Whole Exome Sequencing, Whole Transcriptome Sequencing, and clinical data to generate a risk score and classify patients as platinum-sensitive or resistant. This is particularly significant following FDA approvals for new combination treatments targeting platinum-resistant cases. The ovarian cancer AI signature is available via the Caris Molecular Tumor Board Report when using the MI Cancer Seek test.